PANCREATITIS

Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls

F U Weiss, P Simon, N Bogdanova, J Mayerle, B Dworniczak, J Horst, M M Lerch

Gut 2005;54:1456–1460. doi: 10.1136/gut.2005.064808

See end of article for authors' affiliations

Correspondence to:
Professor M M Lerch,
Department of
Gastroenterology,
Endocrinology and
Nutrition, Ernst-Moritz-
Arndt-Universität
Greifswald, Friedrich-
Loeffler-Strasse 23a,
17487 Greifswald,
Germany; lerch@
uni-greifswald.de

Accepted 12 April 2005
Published online first
29 June 2005

Background: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene—many of which cause cystic fibrosis—have also been reported in patients with chronic pancreatitis. The authors examine whether mild or severe CFTR mutations, homozygous or compound heterozygous CFTR mutations, or even simple cystic fibrosis carrier status alone increases the risk of developing pancreatitis.

Methods: After exclusion of patients with trypsinogen (PRSS1) mutations, cystic fibrosis, or pulmonary disease, and with known risk factors for pancreatitis 67 patients with idiopathic chronic pancreatitis (ICP) from northwest Germany and 60 geographically and ethnically matched controls were recruited. The entire coding region of the CFTR gene was sequenced in all patients and controls. ICP patients were also analysed for serine protease inhibitor Kazal type 1 (SPINK1) gene mutations.

Results: Abnormal CFTR alleles were found to be twice as frequent in ICP patients as in controls (25/134 v 11/120; $p < 0.05$). Three of four severe CFTR mutations detected in patients were compound heterozygous with another abnormal CFTR allele, whereas among controls three severe CFTR mutations were found in heterozygous cystic fibrosis carriers. In ICP patients 19 uncommon/mild mutations, including combinations of the 5T allele with 12TG repeats, were identified compared with only five in controls ($p = 0.012$). Heterozygous SPINK1 mutations were detected in eight ICP patients (15% v 1% in controls) but only one also carried an additional mild CFTR mutation.

Conclusions: These data show that not only compound heterozygosity, but also cystic fibrosis carrier status for different types of CFTR mutations, including uncommon/mild mutations, significantly increase the risk of developing pancreatitis. Although 45% of the study's ICP patients carried predisposing genetic risk factors (for example, mutations in CFTR or SPINK1), the authors found no evidence that the risk conveyed by CFTR mutations depends on co-inherited SPINK1 mutations.

Chronic pancreatitis is a continuing or relapsing inflammatory disease of the exocrine pancreas that is most commonly associated with alcohol abuse or metabolic disorders. In so-called idiopathic pancreatitis patients, in which all common risk factors for pancreatitis had been excluded, disease onset was found to be associated with mutations in three different genes. Those with the highest phenotypic penetrance in this context are mutations in the cationic trypsinogen gene (PRSS1) that segregate with an autosomal dominant variety of hereditary pancreatitis.^{1,2} Furthermore, mutations in the serine protease inhibitor Kazal type 1 (SPINK1) gene were detected in patients with either idiopathic or tropical pancreatitis.^{3–7} In several recent publications a third gene has been suggested to play a role in idiopathic pancreatitis, namely the cystic fibrosis transmembrane conductance regulator (CFTR) gene.^{8–10} It encodes a ubiquitous chloride channel and it is well established that many mutations in this gene cause cystic fibrosis (CF), the most common autosomal recessive inherited disorder in the White population. Cystic fibrosis affects approximately one in 2500 births among Whites but represents a very heterogeneous disorder. More than 1000 different mutations have already been reported in cystic fibrosis patients (updates under <http://www.genet.sickkids.on.ca/cftr/>). On the one hand, the type and severity of the disease depend in a complex manner on the reduction in CFTR protein function, but, on the other hand, the clinical course might also be influenced by environmental factors and other genetic determinants. A combination of severe genetic changes in the two CFTR alleles that reduces CFTR function to about 5%

of physiological levels usually leads to the classical manifestation of cystic fibrosis. Other so-called mild mutations that retain higher CFTR function can cause atypical cystic fibrosis-like phenotypes. Individuals with congenital bilateral absence of the vas deferens (CBAVD), for example, frequently carry mutations in the CFTR gene but show no classical cystic fibrosis clinical phenotype. CBAVD prevents the transport of spermatozoa from testicular or epididymal structures to the vas deferens, resulting in infertility. Approximately 70% of CBAVD patients have one known CFTR mutation and 10% of patients possess two. A similar association with non-cystic fibrosis typical mutations is presently being discussed for primary sclerosing cholangitis.¹¹ These and other reports suggest that different types of mutations in the CFTR gene, causing different degrees of CFTR impairment, can be associated with widely different disease phenotypes.

One obstacle to comprehensive CFTR studies is the large size of its 27 exon spanning gene and the high number of more than 1000 mutations and 200 polymorphisms that have already been reported. Unfortunately, most studies that have addressed the role of CFTR mutations in idiopathic chronic pancreatitis used commercially available screening panels of the 20–30 most common cystic fibrosis causing (rather than pancreatitis causing) CFTR mutations. Whether or not these common cystic fibrosis screening panels happen to include

Abbreviations: CBAVD, congenital bilateral absence of the vas deferens; CFTR, cystic fibrosis transmembrane conductance; ICP, idiopathic chronic pancreatitis; SPINK1, serine protease inhibitor Kazal type 1.

the relevant mutations for other disorders such as pancreatitis seems doubtful and, in view of the mutations reported in, for example, CBAVD, also unlikely. In addition unusual lesions, detectable exclusively by sequencing analysis, might also be present in pancreatitis patients and would not have been identified.

Many studies further compared their observed changes with published historical cohorts rather than using geographically and ethnically matched control groups for their analyses.

This is mostly inappropriate for two reasons: (1) cystic fibrosis mutations are not equally distributed among different populations¹² and carrier frequencies vary from 1/30 among White to 1/90 in Asian cohorts and (2) most historical control cohorts were investigated using commercial mutation panels rather than sequencing techniques and are therefore inappropriate controls for rare or uncommon mutations.

It is therefore not surprising that the question of whether only compound heterozygous CFTR mutations or also an otherwise harmless, heterozygous cystic fibrosis carrier status represents a risk factor for idiopathic pancreatitis remains unresolved. Moreover, it is still unknown whether only severe cystic fibrosis mutations must be regarded as pancreatitis associated mutations or mild and/or variable changes in the CFTR gene convey the same pancreatitis risk.

In order to determine whether or not different types of CFTR mutations affect the risk of developing chronic pancreatitis, and how high that risk may be, we recruited 67 patients with idiopathic chronic pancreatitis (ICP) and 60 geographically and ethnically matched controls. All patients and control subjects were White and from the same, narrowly confined area in northwest Germany. We sequenced the entire coding region of the CFTR gene in all subjects and could firmly determine that compound heterozygous mutation carriers, as well as heterozygotes with mild and uncommon mutations (previously regarded as unaffected cystic fibrosis carriers) have an increased risk of developing chronic pancreatitis. Two thirds of these patients would not have been identified by the commercially available screening panels for the common cystic fibrosis mutations. In combination with an independent population of patients who carry SPINK1 mutations (15%) a total of 45% of our patients with idiopathic chronic pancreatitis ultimately carried identifiable genetic risk factors for the disease.

MATERIALS AND METHODS

Patients and recruitment

Patients and controls were recruited over a five year period at a tertiary referral centre with a large population of out-patients suffering from chronic pancreatitis. The study was performed following a research protocol approved by the local ethics committee and after informed consent was obtained from each patient. All individuals included were White and originated from North-Rhine Westfalia, a populous province in northwest Germany. In order to limit the patient cohort to those with idiopathic chronic pancreatitis, participants were chosen based on unequivocal CT and/or endoscopic retrograde cholangiopancreatography (ERCP) criteria rather than on clinical history or laboratory findings. Patients who reported any known risk factor for pancreatitis, such as a history of nutritive (including alcohol consumption of more than two drinks a day (20 g)), biliary, metabolic, or endocrine disorders, as well as subjects with any evidence of pulmonary diseases or cystic fibrosis, were excluded from the study. Patients identified as mutation carriers in the cationic trypsinogen (PRSS1) gene—as evaluated by complete sequencing of the coding region of the PRSS1 gene—were also excluded, because hereditary pancreatitis caused by PRSS1 mutations is endemic in that region of Germany and

cannot be safely ruled out, based on a negative family history alone.¹³

The remaining panel of ICP patients consisted of 67 people (aged 3–68 years, 40 male and 27 female). The healthy control population consisted of 60 unrelated and unaffected partners of healthy cystic fibrosis carriers (aged 18–50 years, 16 male and 45 female) with an ethnic and geographical background identical to that of the ICP patients. In this control group pancreatic disease and immoderate ethanol consumption had been excluded by structured medical history taking.

Genetic studies

Genomic DNA was extracted from peripheral blood lymphocytes by standard isolation procedures using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). PCR-Amplification of all 27 CFTR exons, including flanking intronic regions, was performed using gene specific primers. Amplicons were sequenced in both directions using the ABI PRISM Dye terminator cycle sequencing reaction kit (Applied Biosystems, Foster City, CA, USA) and electrophoresis was performed on an ABI-3700 Genetic Analyzer (Applied Biosystems). Similarly, the entire coding region (exons 1 to 4) of the SPINK1 gene was amplified by PCR using gene specific primers and each exon was sequenced in both directions in all ICP patients.

Data management and statistical analysis

Statistical analysis was performed using SigmaStat software. Groups were compared using χ^2 test or the Fisher's exact test (when at least one expected cell value in 2×2 table was less than 5). *p* values of below 0.05 were considered statistically significant. Tables were created using Microsoft Excel.

RESULTS AND DISCUSSION

A number of factors have impeded comprehensive investigations of the role of CFTR mutations in idiopathic chronic pancreatitis in the past. These include: (1) the large size of the 27 exon-spanning CFTR gene, (2) the high number of previously reported mutations in patients with cystic fibrosis, (3) the limited number of cystic fibrosis causing mutations that are included in the presently used screening panels for the diagnosis of cystic fibrosis, (4) existence of geographical and ethnic variations in CFTR mutation carrier frequencies, and (5) the lack of reliable data on the frequency of uncommon CFTR mutations in healthy control populations.

To settle the question of whether CFTR mutations convey an increased risk for developing chronic pancreatitis, we started a comprehensive sequencing study involving a cohort of 67 patients with idiopathic chronic pancreatitis as well as a geographically and ethnically matched control group.

Among 67 ICP patients we identified a total number of 25 abnormal CFTR alleles, which amounts to twice the allele frequency in healthy controls (11 abnormal CFTR alleles in 60 controls; 18.6% *v* 9.2%, *p* < 0.05; details in tables 1 and 2).

Detected mutations in 60 control subjects included three heterozygous classical mutations $\Delta F508$, four mild CFTR mutations, and the T5 allele in intron 8 of the CFTR gene in additional four subjects. In the ICP cohort on the other hand, four patients were compound heterozygous for two gene mutations, nine patients were carriers of a single sequence variation, and in an additional eight patients the T5 sequence variant was detected. Due to the four compound heterozygous ICP patients the overall number of patients carrying CFTR mutations was 21. Although this is nearly twice the prevalence in controls the difference misses statistical significance (21/67; 31% *v* 11/60; 18.3%; *p* = 0.14, see also table 3).

Table 1 CFTR and SPINK1 sequence variations identified in 30 of the 67 ICP patients

Patient	Sex	CFTR mutation	T allele	TG repeats	PST1 mutation
1	M	ΔF508/R117H	7/7	9/10	-/-
2	W	ΔF508/A1087P	7/9	10/11	-/-
3	M	ΔF508/D1152H	7/9	10/10	-/-
4	M	S1235R/R668C	7/7	11/12	-/-
5	M	2184insA/-	7/7	10/12	-/-
6	M	R31C/-	7/7	10/11	-/-
7	M	R75Q/-	7/7	11/11	-/-
8	M	R347P/-	7/7	11/12	-/-
9	M	S1235R/-	7/7	11/12	-/-
10	W	S1235R/-	7/7	11/12	-/-
11	M	G576A/-	7/7	10/10	-/-
12	W	M348V/-	7/9	10/10	-/-
13	M	V754M/-	7/7	10/11	-/-
14	M	-/-	5/7	11/12	-/-
15	W	-/-	5/7	11/12	-/-
16	M	-/-	5/7	11/12	-/-
17	W	-/-	5/9	11/12	-/-
18	M	-/-	5/7	11/12	-/-
19	M	-/-	5/7	10/10	-/-
20	W	-/-	5/7	10/10	-/-
21	W	-/-	5/7	11/12	N34S/-
22	W	-/-	7/7	10/11	N34S/-
23	M	-/-	7/9	10/11	N34S/-
24	M	-/-	7/7	11/11	N34S/-
25	M	-/-	7/7	11/11	N34S/-
26	W	-/-	7/7	11/11	N34S/-
27	M	-/-	7/7	11/11	N34S/-
28	W	-/-	7/7	10/11	N34S/-
29	W	-/-	7/7	11/11	P55S/-
30	W	-/-	7/7	11/11	IVS3+2TC/-

Three of the four compound heterozygous ICP patients carried one severe ΔF508 mutation (genotypes: ΔF508/R117H, ΔF508/A1087P, ΔF508/D1152H) and one carried two mild mutations (S1235R/R668C). Taking into account the allele frequency of severe and mild mutations in our control population (7/120; 5.8%) the calculated frequency of compound heterozygous subjects would be 0.34% in the normal population and therefore appears about 18-fold higher in the ICP patient group (4/67; 6%). This points to an important role of combined genetic changes in the two CFTR alleles that may additively reduce the physiological levels and function of CFTR. None of the patients, however, had a combination of two severe CFTR mutations, as would be expected from a cohort from which all individuals with symptoms of cystic fibrosis or evidence for pulmonary disease had been excluded.

In the group of ICP patients being heterozygous for a single CFTR mutation one severe (2184insA, this insertion causes a frame shift) and eight mild/uncommon mutations (2× S1235R, R31C, R75Q, R347P, G576A, M348V, and V754M) were identified. M348V and A1087P present novel molecular changes in the CFTR gene with so far undetermined consequences on CFTR function. A1087P affects the intracellular loop between the transmembrane domains M10 and M11 and is most probably a mild missense mutation whereas M348V is located in the sixth transmembrane domain of the protein, where the wild type sequence has been conserved during evolution. Both molecular changes have never been identified in control groups, so we have to consider them as pathogenic.

When we compared abnormal CFTR alleles neither severe nor mild/uncommon mutations by themselves were significantly increased in the ICP patient group (see table 3). Also simple 5T alleles were not significantly increased in ICP patients (8/134 v 3/120; $p = 0.29$). Interestingly however, six of those eight ICP patients with a 5T allele in intron 8 were also carriers of 12 TG repeats (located in close proximity in

Table 2 CFTR sequence variations identified in 11 of 60 healthy controls

Control group	Number
ΔF508/-	3
R117H/-	2
I148T/-	1
L997F/-	1
5T/12TG	1
5T/11TG	3

the same intron), a combination that is known to increase aberrant exon 9 splicing.^{14 15} In two recent publications^{16 17} the differential formation of secondary structures by dinucleotide repeats TG12, or TG13 has been reported to affect CFTR splicing efficiency and therefore to be of relevance for the discrimination between benign and pathogenically relevant 5T alleles. In our control group we found 5T alleles in four individuals of which only one also carried 12 TG repeats. Allelic variations of 5T–12TG were therefore 5.2 times more frequent in the patient group (6/134 v 1/120; $p = 0.16$) whereas combined allele frequencies of CFTR mutations and 5T–12TG combinations, but excluding “benign” 5T alone, were increased to statistically significant levels among ICP patients (23/134 v 8/120; $p = 0.018$). As we had excluded patients with symptoms of cystic fibrosis or evidence for pulmonary disease from the study, the number of severe CFTR mutations might have been biased towards a low prevalence. This restriction, however, was necessary to discriminate between pancreatic dysfunction as one possible symptom of cystic fibrosis as opposed to being caused by idiopathic pancreatitis. If we therefore disregard severe mutations and compare only mild CFTR mutations (which, when heterozygous do not cause cystic fibrosis) we find that mild CFTR mutations, including combination of 5T–12TG repeats, are also increased to significant levels in ICP patients when compared with controls (19/134 v 5/120; $p = 0.012$). Therefore, in addition to compound heterozygous patients, subjects who carry one mild CFTR mutation or a 5T–12TG combination must now be considered to be at an increased risk of developing idiopathic chronic pancreatitis.

Recently an analysis of CFTR mutations in four population samples with a total of 191 individuals was reported that used a novel denaturing gradient gel electrophoresis (DGGE) approach which is estimated to detect about 95% of all mutations.¹⁸ This study is presently the largest analysis of healthy controls and identified 30 CFTR mutations and 17 5T alleles. However, the presence or absence of the more functionally relevant combination of 5T alleles with 12TG repeats had not been evaluated. Excluding 5T alleles and 5T–12TG combinations the allele frequency of CFTR mutations in that study was approximately 7.8%. The population samples had been gathered from four different regions in southern Europe and the observed mutation frequencies and their distribution were not significantly different from those in our control population (5.8%).

In a study by Ockenga *et al*, the authors analysed 20 German ICP patients using a cystic fibrosis screening panel covering 32 frequent CFTR mutations.¹⁰ Six patients carrying at least one abnormal CFTR gene were identified (30%) and only one patient was compound heterozygote for two mutations (1/20, 5%). Studies by other groups^{19–21} also identified patients with idiopathic chronic pancreatitis that were compound heterozygote for two mutations (3/14, 21%; 9/39, 23%; 4/39, 10%). The reason why numbers for compound heterozygous ICP patients in these studies are diverse (4/67 = 6% in our study) may be due to differences

Table 3 CFTR allele frequencies in ICP patients and controls

	ICP patients	Controls	p Value
Abnormal CFTR alleles (affected subjects)	25/134 (21/67)	11/120 (11/60)	0.047* (0.14)
Compound heterozygous alleles	8/134	0/120	0.018*
Severe CFTR mutations	4/134	3/120	0.88
Mild/uncommon CFTR mutations (excluding 5T alleles)	13/134	4/120	0.08
Simple 5T alleles	8/134	4/120	0.49
5T-12TG combination	6/134	1/120	0.16
Mild/uncommon CFTR mutations including 5T-12TG, excluding mere 5T alleles	19/134	5/120	0.012*
All CFTR mutations, including 5T-12TG, excluding mere 5T alleles	23/134	8/120	0.018*

*p values below 0.05 are considered statistically significant.

in patient recruitment, the catchment populations, or the stringency with which cystic fibrosis patients were excluded.

To date it remains unclear whether in these compound heterozygotes the impairment of CFTR function is not yet severe enough to cause the onset of classic cystic fibrosis or whether pancreatitis is an independent disease entity caused by diminished CFTR function. Affected patients could therefore suffer from either an atypical variety of cystic fibrosis or from a completely different disease—ICP—that is also associated with CFTR mutations.

Concerning the relevance of 5T alleles it is true that 5T alleles have never been shown to be in linkage disequilibrium with severe CFTR mutations like $\Delta F508$. When found in trans position with a severe cystic fibrosis causing mutation some individuals, however, have been reported to develop non-classic cystic fibrosis, others were diagnosed with male infertility caused by CBAVD, while approximately 40% had no detectable phenotypic changes.^{22, 23} In 91% of clinically affected individuals abnormal TG repeats were identified¹⁶ and the TG repeat number therefore seems to correlate closely with the pathogenicity of the 5T allele. 5T alleles in combination with a normal allele or a normal TG repeat number have not been considered as disease causing. The increased frequency of heterozygous uncommon/mild mutations, including the 5T-12TG combination, among patients with ICP may indicate that pathogenic processes affecting the exocrine pancreas may already be operative at levels of CFTR functional impairment that are still compatible with male fertility, normal pulmonary physiology, and absence of cystic fibrosis. How heterozygous CFTR mutations could predispose patients to developing ICP is not readily understood. One possible explanation would be the combination with defects in other gene products that could result in a synergistic pathogenetic effect on acinar cell function.

We sought to test this hypothesis for a possible interaction of CFTR mutations with mutations in the SPINK1 gene, for which an association with idiopathic and tropical pancreatitis has previously been reported. Sequencing analysis of the entire coding region of the SPINK1 gene revealed that 10 patients were found to carry SPINK1 mutations (8× N34S, 1× P55S, and 1× IVS3+2TC). All SPINK1 mutation carriers had normal CFTR alleles with the exception of one patient who was heterozygous for the N34S mutation and a 5T-12TG combination. This result constitutes a 15% prevalence of SPINK1 mutations among our ICP patients—versus 1% in the ethnically matched controls of our catchment area according to one of our recent studies²⁴—and confirms the previous finding of an increased frequency of SPINK1 mutations in chronic pancreatitis.³⁻⁵ However, it also indicates that a co-occurrence of SPINK1 mutations is not required for CFTR mutations to confer their risk for developing pancreatitis. Similar findings were reported by Bernadino *et al* who investigated 82 Brazilian ICP patients and 200 controls.²⁵ They found that about 10% of the Brazilian patients carried

CFTR mutations whereas only a single patient carried a SPINK1 mutation. It therefore appears that in Brazil, very unlike the Indian subcontinent, alterations in the SPINK1 gene play no role in the pathogenesis of pancreatitis. It also confirms our interpretation that CFTR mutations convey an increased risk for the development of pancreatitis that is independent of co-inherited mutations in the SPINK1 gene. A disease modifier role of PRSS1 mutations on alterations in the CFTR gene was already ruled out by our exclusion criteria during patient recruitment.

If we had used commercially available screening panels to identify CFTR alterations, rather than DNA sequencing, we would have missed 16 of the 25 uncovered mutations. According to our study, the risk of developing chronic pancreatitis for a heterozygous carrier of a CFTR mutation (regardless of its severity) is increased approximately three- to fourfold over that of the normal population. The risk for a compound heterozygous individual whose mutations include a severe type, on the other hand, is presumably increased several 100-fold over that of the control population. From the latter group with the highest risk of developing chronic pancreatitis the majority would, after all, have been identified using commercially available cystic fibrosis screening panels although their compound heterozygous status would have been missed.

At present the routine testing of chronic pancreatitis patients for either CFTR or SPINK1 mutations—using mutation panels or full sequencing—outside of research protocol driven studies cannot be recommended and remains without clinical consequences.

Among White populations the healthy carriers of severe cystic fibrosis causing CFTR mutations (about 5%) are thought to be at an increased risk of developing chronic pancreatitis. Our study has determined that not only compound heterozygous carriers of CFTR mutations but also carriers of mild/uncommon CFTR mutations (about 8% of the population) carry an increased risk of developing chronic pancreatitis. The cellular mechanism through which a functionally impaired CFTR leads to the onset of pancreatitis still needs to be elucidated.

ACKNOWLEDGEMENTS

The work was supported by grants from the Deutsche Forschungsgemeinschaft (MML), the BMBF (NBL-3), The Krupp-Stiftung (FUW, JM, and MM), and the Deutsche Krebshilfe/Mildred-Scheel-Stiftung (MML and JM). We thank H Baumhöver, U Antkowiak, S Pitschner, and S Greiner for expert technical assistance. We further wish to thank Jonathan Cohn, Duke University, for helpful advice and stimulating discussion.

Authors' affiliations

F U Weiss*, P Simon*, J Mayerle, M M Lerch, Department of Gastroenterology, Endocrinology and Nutrition, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany

N Bogdanova*, B Dworniczak, J Horst, Department of Human Genetics, Westfälische Wilhelms-Universität Münster, Münster, Germany

*Equal contributors.

Competing interests: none declared.

REFERENCES

- 1 **Simon P**, Weiss FU, Sahin-Toth M, *et al*. Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 → Cys) that alters autoactivation and autodegradation of cationic trypsinogen. *J Biol Chem* 2002;**277**:5404–10.
- 2 **Whitcomb DC**, Gorry MC, Preston RA, *et al*. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nat Genet* 1996;**14**:141–5.
- 3 **Chen JM**, Mercier B, Audrezet MP, *et al*. Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. *Gastroenterology* 2001;**120**:1061–4.
- 4 **Putzer RH**, Barmada MM, Brunskill AP, *et al*. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. *Gastroenterology* 2000;**119**:615–23.
- 5 **Witt H**, Luck W, Hennies HC, *et al*. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. *Nat Genet* 2000;**25**:213–16.
- 6 **Bhatia E**, Balasubramaniam K, Rajeswari J, *et al*. Absence of association between SPINK1 trypsin inhibitor mutations and Type 1 or 2 diabetes mellitus in India and Germany. *Diabetologia* 2003;**46**:1710–11.
- 7 **Weiss FU**, Simon P, Witt H, *et al*. SPINK1 mutations and phenotypic expression in patients with pancreatitis associated with trypsinogen mutations. *J Med Genet* 2003;**40**:e40.
- 8 **Cohn JA**, Friedman KJ, Noone PG, *et al*. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. *N Engl J Med* 1998;**339**:653–8.
- 9 **Shaner N**, Schwarz M, Malone G, *et al*. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med* 1998;**339**:645–52.
- 10 **Ockenga J**, Stuhmann M, Ballmann M, *et al*. Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. *Am J Gastroenterol* 2000;**95**:2061–7.
- 11 **Sheth S**, Shea JC, Bishop MD, *et al*. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. *Hum Genet* 2003;**113**:286–92.
- 12 **Bobadilla JL**, Macek M Jr, Fine JP, *et al*. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. *Hum Mutat* 2002;**19**:575–606.
- 13 **Simon P**, Weiss FU, Zimmer KP, *et al*. Spontaneous and sporadic trypsinogen mutations in idiopathic pancreatitis. *JAMA* 2002;**288**:2122.
- 14 **Cuppens H**, Lin W, Jaspers M, *et al*. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. *J Clin Invest* 1998;**101**:487–96.
- 15 **Niksic M**, Romano M, Buratti E, *et al*. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. *Hum Mol Genet* 1999;**8**:2339–49.
- 16 **Groman JD**, Hefferon TW, Casals T, *et al*. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. *Am J Hum Genet* 2004;**74**:176–9.
- 17 **Hefferon TW**, Groman JD, Yurk CE, *et al*. A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. *Proc Natl Acad Sci U S A* 2004;**101**:3504–9.
- 18 **Bombieri C**, Giorgi S, Carles S, *et al*. A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals. *Hum Genet* 2000;**106**:172–8.
- 19 **Noone PG**, Zhou Z, Silverman LM, *et al*. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. *Gastroenterology* 2001;**121**:1310–19.
- 20 **Castellani C**, Gomez Lira M, Frulloni L, *et al*. Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in idiopathic pancreatitis. *Hum Mutat* 2001;**18**:166.
- 21 **Audrezet MP**, Chen JM, Le Marechal C, *et al*. Determination of the relative contribution of three genes—the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene—to the etiology of idiopathic chronic pancreatitis. *Eur J Hum Genet* 2002;**10**:100–6.
- 22 **Chillon M**, Casals T, Mercier B, *et al*. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. *N Engl J Med* 1995;**332**:1475–80.
- 23 **Zielenski J**, Patrizio P, Corey M, *et al*. CFTR gene variant for patients with congenital absence of vas deferens. *Am J Hum Genet* 1995;**57**:958–60.
- 24 **Threadgold J**, Greenhalf W, Ellis I, *et al*. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. *Gut* 2002;**50**:675–81.
- 25 **Bernardino AL**, Guarita DR, Mott CB, *et al*. CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients. *JOP* 2003;**4**:169–77.